Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Spectrum Asset Management Inc. NB CA

Spectrum Asset Management Inc. NB CA decreased its holdings in Edwards Lifesciences Co. (NYSE:EW) by 6.4% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 35,633 shares of the medical research company’s stock after selling 2,421 shares during the quarter. Spectrum Asset Management Inc. NB CA’s holdings in Edwards Lifesciences were worth $2,638,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the stock. Harbor Capital Advisors Inc. raised its holdings in shares of Edwards Lifesciences by 2.5% during the fourth quarter. Harbor Capital Advisors Inc. now owns 11,135 shares of the medical research company’s stock valued at $824,000 after acquiring an additional 273 shares during the period. Nordea Investment Management AB raised its stake in Edwards Lifesciences by 34.6% during the 4th quarter. Nordea Investment Management AB now owns 4,057,013 shares of the medical research company’s stock valued at $301,355,000 after purchasing an additional 1,043,484 shares during the period. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST lifted its holdings in shares of Edwards Lifesciences by 6.7% in the fourth quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST now owns 4,800,000 shares of the medical research company’s stock valued at $355,344,000 after purchasing an additional 300,000 shares in the last quarter. Sivik Global Healthcare LLC purchased a new stake in shares of Edwards Lifesciences in the fourth quarter valued at $3,702,000. Finally, Avanza Fonder AB acquired a new stake in shares of Edwards Lifesciences in the fourth quarter worth $4,845,000. Institutional investors own 79.46% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the company. Robert W. Baird reduced their price objective on Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating for the company in a research note on Friday, October 25th. Morgan Stanley reissued an “equal weight” rating and issued a $70.00 price target on shares of Edwards Lifesciences in a research report on Friday, October 11th. Daiwa America downgraded shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 30th. Barclays increased their target price on shares of Edwards Lifesciences from $85.00 to $88.00 and gave the stock an “overweight” rating in a research report on Monday, December 2nd. Finally, Citigroup boosted their price target on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. One equities research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $79.19.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 500 shares of Edwards Lifesciences stock in a transaction on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total transaction of $34,380.00. Following the sale, the vice president now owns 23,189 shares in the company, valued at $1,594,475.64. The trade was a 2.11 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total transaction of $327,850.00. Following the completion of the sale, the vice president now directly owns 46,936 shares in the company, valued at $3,077,593.52. This trade represents a 9.63 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 8,000 shares of company stock valued at $547,430 in the last three months. Company insiders own 1.27% of the company’s stock.

Edwards Lifesciences Stock Down 1.6 %

EW stock opened at $70.96 on Friday. The stock has a market capitalization of $41.85 billion, a price-to-earnings ratio of 10.24, a price-to-earnings-growth ratio of 3.72 and a beta of 1.11. The company has a 50-day moving average of $72.49 and a two-hundred day moving average of $69.54. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $96.12. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.